PodMed – Week of June 5, 2017
This week’s topics include treating resistant hepatitis C infection, a new regimen for breast cancer, evolution of non-small cell lung cancer, and minocycline for MS. Program notes: 0:44 Evolution of lung cancer 1:42 Did genetic analysis of whole tumor 2:42 Insight into how to target therapy 3:13 Bad actor breast cancers 4:16 Disease free survival […] (Source: Johns Hopkins Medicine Weekly Health News)
Source: Johns Hopkins Medicine Weekly Health News - June 2, 2017 Category: Consumer Health News Authors: Elizabeth Tracey Johns Hopkins Medicine Tags: All Podcasts Cancer Infectious diseases Neurology And Neurosurgery PodMed Source Type: podcasts
Testing, Care, and Cure of Hepatitis C
Despite many challenges, an increasing number of HCV-infected patients are being treated and cured, and many can be managed in primary care. (Source: Medscape Infectious Disease Podcast)
Source: Medscape Infectious Disease Podcast - May 5, 2017 Category: Infectious Diseases Authors: Medscape Source Type: podcasts
Morning Report: Bisphosphonates; T1DM in Adults; Hep B and C
Dr Arefa Cassoobhoy highlights some of this week ' s most important medical news, including new-onset type 1 diabetes in adults, treating hepatitis C, and the effect of bisphosphonates on mortality. (Source: Medscape Internal Medicine Podcast)
Source: Medscape Internal Medicine Podcast - September 30, 2016 Category: Internal Medicine Authors: Medscape Source Type: podcasts
How does maximizing shareholder value distort drug development?
With the emergence of sofobuvir, a new direct acting antiviral, treatment for Hepatitis C infection is currently undergoing it's greatest change since the discovery of the virus 25 years ago.
However Gilead, who manufacture the treatment, are under fire for the cost of the druge - around $90 000 for a course of treatment.
Victor Roy, doctoral... (Source: The BMJ Podcast)
Source: The BMJ Podcast - July 28, 2016 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
How does maximizing shareholder value distort drug development?
With the emergence of sofobuvir, a new direct acting antiviral, treatment for Hepatitis C infection is currently undergoing it's greatest change since the discovery of the virus 25 years ago.
However Gilead, who manufacture the treatment, are under fire for the cost of the druge - around $90 000 for a course of treatment.
Victor Roy, doctoral... < div class="feedflare" > < a href="http://feeds.bmj.com/~ff/bmj/podcasts?a=Jb0mLYezd1U:tNwQPGVMeOg:yIl2AUoC8zA" > < img src="http://feeds.feedburner.com/~ff/bmj/podcasts?d=yIl2AUoC8zA" border="0" > < /img > < /a > < a href="http://feeds.bmj.com/~ff/bmj/podcasts?a=Jb0mLYezd1U:...
Source: The BMJ Podcast - July 28, 2016 Category: Journals (General) Authors: BMJ talk medicine Source Type: podcasts
How does maximizing shareholder value distort drug development?
With the emergence of sofobuvir, a new direct acting antiviral, treatment for Hepatitis C infection is currently undergoing it's greatest change since the discovery of the virus 25 years ago.
However Gilead, who manufacture the treatment, are under fire for the cost of the druge - around $90 000 for a course of treatment.
Victor Roy, doctoral researcher at the University of Cambridge, discusses how the new drug was discovered and came to market, and what happened to the profits from sale.
Read the full analysis:
http://www.bmj.com/content/354/bmj.i3718 (Source: The BMJ Podcast)
Source: The BMJ Podcast - July 28, 2016 Category: General Medicine Authors: BMJ Group Source Type: podcasts
TWiV 393: Lovers and livers
Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler The TWiVerati revisit possible sexual transmission of Zika virus, and reveal how a cell protein that allows hepatitis C virus replication in cell culture enhances vitamin E mediated protection against lipid peroxidation. Become a patron of TWiV! Links for this episode Late sexual transmission of Zika virus (Lancet) Zika virus disease in US (CDC) Zika virus lab accident (ABC News) Mosquito eradication (virology blog) Florida mosquito control (TWiV 111) How tequila mosquito (TWiV 178) SEC14L2 allows HCV replication in cell culture (Nature) Lipid pero...
Source: This Week in Virology - MP3 Edition - June 12, 2016 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
TWiV 389: Alphabet hepatitis with Stan Lemon
Host: Vincent Racaniello Guest: Stan Lemon Vincent speaks with Stan Lemon about his career in virology, from early work on Epstein Barr virus, through making essential discoveries about hepatitis A virus, hepatitis C virus, and rhinoviruses. Links for this episode Live in Edmonton, Eh? (TWiV 235) Replication of EBV in epithelial cells (Nature) Returning to Carolina after 14 years Evolutionary origins of hepatitis A virus (TWiV 265) cre in rhinovirus genome (RNA) Naked viruses that aren't always naked (Ann Rev Virol) miR-122 and hepatitis C virus RNA (Cell Host Micr) This episode is sponsored by CuriosityStream. Get two...
Source: This Week in Virology - MP3 Edition - May 15, 2016 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
TWiV 365: Blood, feuds, and a foodborne disease
Hosts: Vincent Racaniello, Alan Dove, and Kathy Spindler
For a TWiV Thanksgiving, Vincent, Alan, and Kathy trace the feud over genome editing, a new virus discovered in human blood, and the origins of hepatitis A virus.
Links for this episode
Battle over genome editing (Wired) 10:05
First description of CRISPR in E. coli (J Bacteriol) 14:00
Cas genes identified (Mol Micro) 14:20
CRISPR-Cas provides immunity to bacterial viruses (Science) 15:35
Cas9-crRNA complex mediates DNA cleavage (PNAS) 16:55
Dual RNA-guided DNA endonuclease in bacterial immunity (Science) 17:50
Genome engineering using CRISPR/Cas (S...
Source: This Week in Virology - MP3 Edition - November 29, 2015 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
FDA Drug Safety Podcast: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
On October 22, 2015 FDA announced it is warning that hepatitis C treatments Viekira Pak and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - October 30, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Prevention of Perinatal Hepatitis B Transmission
Some infants are developing HBV infection despite being vaccinated. Which infants are at risk, and what can be done to prevent HBV infection in these infants? (Source: Medscape Infectious Disease Podcast)
Source: Medscape Infectious Disease Podcast - September 8, 2015 Category: Infectious Diseases Authors: Medscape Source Type: podcasts
Entecavir vs. Lamivudine in Preventing Hepatitis B Reactivation in Untreated DLBCL
In this study researchers compared the effectivene...
Author: feeds
Added: 06/30/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 30, 2015 Category: Cancer & Oncology Source Type: podcasts
DCV/ASV/BCV for HCV Infection With Cirrhosis
Interview with Andrew J. Muir, MD, author of Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - May 5, 2015 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
